Article
Excerpt from the Press Release: CONCORD, Mass., March 30, 2023 /PRNewswire/ — Comanche Biopharma Corp., a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for Comanche’s novel, siRNA therapy to treat preeclampsia. Preeclampsia is a prevalent hypertensive disorder of pregnancy for which there…
Read More
— Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series by 2025 — — The Nine Incremental Serotypes in VAX-24 Cover an Additional 20-25 Percent of Strains Causing Invasive Pneumococcal Disease Over the Current Standard-of-Care PCV in Infants — Excerpt from the Press Release: SAN CARLOS, Calif., March 30, 2023…
Read More
Peptide-level insights from deep, unbiased proteomics enable protein variant analysis of patient samples, revealing potential non-small cell lung cancer biomarkers Excerpt from the Press Release: REDWOOD CITY, Calif., March 29, 2023 (GLOBE NEWSWIRE) — Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced a new scientific publication…
Read More
Bigfoot strengthens its technology portfolio, enhancing the company’s ability to deliver on its mission to reduce the burden of diabetes for people who require insulin Excerpt from the Press Release: MILPITAS, Calif.–(BUSINESS WIRE)–Bigfoot Biomedical (Bigfoot), a leader in developing intelligent connected injection support systems, today announced the acquisition of a reinforcement learning algorithm for the…
Read More
The planned Phase 3 program consists of three trials, SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes to evaluate the safety and efficacy of efruxifermin (EFX) in patients with NASH SYNCHRONY Histology and SYNCHRONY Real-World are expected to begin enrollment in the second half of this year Consistent with the encouraging clinical profile to date reported…
Read More
– BBP-398, an investigational SHP2 inhibitor, is a potentially best-in-class therapy for use in combination approaches, which is shown by preclinical findings demonstrating its safety profile, continuous, once-daily dosing regimen and synergistic efficacy to treat cancers driven by KRAS mutations – If successful, the combination of investigational therapy BBP-398 and OPDIVO has the potential to…
Read More
First in human study will evaluate safety, tolerability, and pharmacokinetic parameters of NRL-1049, a Rho kinase (ROCK) inhibitor Excerpt from the Press Release: SAN DIEGO, Calif., March 24, 2023 /PRNewswire/ — Neurelis, Inc., announced the first two cohorts dosed in the investigational clinical trial of NRL-1049, a Rho kinase (ROCK) inhibitor, a potential treatment for…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Mar. 24, 2023– Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces enrollment of the first patient in the FORESEE clinical trial with the Company’s proprietary cerebrospinal fluid assay CNSide (NCT05414123). This first patient was seen at the UT Southwestern Medical Center,…
Read More
Excerpt from the Press Release: SAN FRANCISCO, CA / ACCESSWIRE / March 23, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) and its wholly owned subsidiary Napo Pharmaceuticals (Napo) today announced that Dr. Kelly Shanahan, a former clinician and a metastatic breast cancer patient who is now a full-time independent patient advocate, has…
Read More
Excerpt from the Press Release: SAN MATEO, Calif.–(BUSINESS WIRE)–Cala, the bioelectronic medicine leader setting a new standard of care for chronic disease, today announced meeting the primary endpoint on an interim analysis of a prospective, randomized, controlled study. This study, “RWE Study Utilizing the Cala Trio Device in Patients With Essential Tremor” (clinicaltrials.gov NCT05540626), demonstrated…
Read More